Please wait a minute...
Reviews in Cardiovascular Medicine  2014, Vol. 15 Issue (S1): 38-46     DOI: 10.3908.ricm15S1S001
Review Previous articles |
Management of Dyslipidemia in Patients With Human Immunodeficiency Virus
Peter Shalit
Swedish Medical Center, Seattle, WA
Download:  PDF(254KB)  ( 105 )
Export:  BibTeX | EndNote (RIS)      
Dyslipidemias are more common in the patient population with human immunodeficiency virus (HIV). Combination antiretroviral therapy (ART) has dramatically reduced HIV-associated morbidity and mortality and has transformed HIV disease into a chronic, manageable condition. As a result, non–AIDS-related illnesses, including cardiovascular diseases, are now the leading causes of death in the HIV-infected population. Optimizing fasting lipid parameters plays an important role in reducing cardiovascular risk in this population. This review focuses on the management of dyslipidemia in HIV-infected individuals treated with combination ART.
Key words:  Human immunodeficiency virus      Dyslipidemia      Antiretroviral therapy      Cardiovascular risk     
Published:  20 January 2014     

Cite this article: 

Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38-46.

URL:     OR

[1] María M. Adeva-Andany, Carlos Fernández-Fernández, Natalia Carneiro-Freire, Elvira Castro-Quintela, Ana Pedre-Piñeiro, Mónica Seco-Filgueira. Insulin resistance underlies the elevated cardiovascular risk associated with kidney disease and glomerular hyperfiltration[J]. Reviews in Cardiovascular Medicine, 2020, 21(1): 41-56.
[2] Michele Provenzano, Giuseppe Coppolino, Teresa Faga, Carlo Garofalo, Raffaele Serra, Michele Andreucci. Epidemiology of cardiovascular risk in chronic kidney disease patients: the real silent killer[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 209-220.
[3] Jun Zhang, Natalia de Albuquerque Rocha, and Peter A. McCullough. Contribution of ApoCIII to Diabetic Dyslipidemia and Treatment With Volanesorsen[J]. Reviews in Cardiovascular Medicine, 2018, 19(1): 13-19.
[4] Vasiliki Katsi, Manolis S. Kallistratos, Antonios N. Pavlidis, Nikos Karpettas, Ioannis Skoumas, Nikonas Pavleros, Athanasios J. Manolis, Christos Pitsavos, Dimitris Tousoulis, Christodoulos Stefanadis, Ioannis Kallikazaros. The Mystery of High-density Lipoprotein: Quantity or Quality? Update on Therapeutic Strategies[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 9-19.
[5] Virginia A. Triant. Epidemiology of Coronary Heart Disease in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 1-8.
[6] Paolo Gresele, Emanuela Falcinelli, Stefania Momi, Daniela Francisci, Franco Baldelli. Highly Active Antiretroviral Therapy–related Mechanisms of Endothelial and Platelet Function Alterations[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 9-20.
[7] Patrick W.G. Mallon. Impact of Nucleoside Reverse Transcriptase Inhibitors on Coronary Heart Disease[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 21-29.
[8] Giovanni Guaraldi, Antonella Santoro, Chiara Stentarelli, Kety Luzi. Impact of Antiretroviral Medications on Fasting Lipid Parameters[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 30-37.
[9] Peter A. McCullough, Amina B. Ahmed, Marc T. Zughaib, Eric D. Glanz, Michael J. Di Loreto. Treatment of Hypertriglyceridemia With Fibric Acid Derivatives: Impact on Lipid Subfractions and Translation Into a Reduction in Cardiovascular Events[J]. Reviews in Cardiovascular Medicine, 2011, 12(4): 173-185.
[10] Norman E. Lepor, Gerald M. Pohost. Cardiovascular Imaging to Risk-Stratify in Chronic Angina[J]. Reviews in Cardiovascular Medicine, 2009, 10(S1): 30-37.
[11] Abdullah Hanna-Moussa, Michael J. Gardner, L. Romayne Kurukulasuriya, James R. Sowers. Dysglycemia/Prediabetes and Cardiovascular Risk Factors[J]. Reviews in Cardiovascular Medicine, 2009, 10(4): 202-208.
[12] Gustavo A. Cardenas, Carl J. Lavie, Vanessa Cardenas, Richard V. Milani, Peter A. McCullough. The Importance of Recognizing and Treating Low Levels of High-Density Lipoprotein Cholesterol: A New Era in Atherosclerosis Management[J]. Reviews in Cardiovascular Medicine, 2008, 9(4): 239-258.
[13] Thomas D. Giles. A Perspective on Telmisartan and Cardiovascular Risk[J]. Reviews in Cardiovascular Medicine, 2007, 8(3): 154-159.
[14] Donna H. Ryan. The Relationship Among Risk Factor Clustering, Abdominal Obesity, and Residual Risk for Cardiovascular Events[J]. Reviews in Cardiovascular Medicine, 2007, 8(1): 9-16.
[15] Keith C. Ferdinand, Keith C. Ferdinand. The Epidemic of Diabetes Mellitus and the Metabolic Syndrome in African Americans[J]. Reviews in Cardiovascular Medicine, 2004, 5(S3): 28-33.
No Suggested Reading articles found!